The purpose of this study is to determine the safety and acceptability of a vaginal
microbicide in HIV uninfected sexually active women.
Study hypothesis: The vaginal microbicide 1% tenofovir will be safe and well tolerated in HIV
uninfected women who are in good general health.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute of Mental Health (NIMH) National Institute on Drug Abuse (NIDA)